J&J scores an­oth­er PhI­II win for Er­lea­da as it con­tin­ues to build a block­buster fran­chise

Just un­der a year since J&J won ap­proval from the FDA to start mar­ket­ing Er­lea­da (apa­lu­tamide) for non-metasta­t­ic prostate can­cer, the phar­ma gi­ant has now nailed down the late-stage da­ta it needs to prove that it works in metasta­t­ic pa­tients as well.

The phar­ma gi­ant said Wednes­day morn­ing that the mon­i­tor­ing com­mit­tee on the TI­TAN study called it, flag­ging the study for its suc­cess on both the co-pri­maries: ra­di­ograph­ic pro­gres­sion-free sur­vival as well as over­all sur­vival. The ac­tu­al da­ta will be post­ed lat­er this year with as much fan­fare as the com­pa­ny will be able to muster.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.